St. John’s wort vs. Paxil
This article was originally published in The Tan Sheet
Executive Summary
Dr. Willmar Schwabe Pharmaceuticals' St. John's wort extract WS 5570 is "at least as effective as" GlaxoSmithKline's antidepressant Paxil (paroxetine) "over six weeks of acute treatment in out-patients with moderate or severe unipolar major depression," a Schwabe-funded study finds. The results "support the use of [St. John's wort] as an alternative to standard antidepressants in moderate to severe depression, especially as well-tolerated," A. Szegedi, Charite Universitatsmedizin, Berlin, et al., report in the Feb. 11 British Medical Journal. The study's 251 participants, who ranged in age from 18-70, were randomized to either 900 mg/day WS 5570 or 20 mg paroxetine once daily for six weeks. Response to treatment was measured by change in score on the Hamilton scale from baseline to day 42. The lead author has received consultancy fees from the firm, and two other study authors are employees of Schwabe...
You may also be interested in...
St. John’s Wort “Significantly More Effective” Than Prozac, Study Finds
St. John's wort is more effective at treating major depressive disorder (MDD) than fluoxetine (Eli Lilly's Prozac), according to a study published in the October Journal of Clinical Psychopharmacology.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.